December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

1,063.56 -21.63 (-1.99%)
Official Closing Price Updated: 7:00 PM EST, Jan 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2
...
26 27 28 29 30 31 32 33 34
...
99 100 Next >
News headline image
3 Stocks to Buy and Hold Forever ↗
These stocks are built for the long run. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Skye Bioscience Advances Position In Competitive Obesity Market With Promising Data ↗
Skye Bioscience's latest data show nimacimab boosted tirzepatide's weight loss effects and reduced obesity treatment rebound risk. 
Via Benzinga
News headline image
Is Eli Lilly Stock a Buy After Gaining 5% in 1 Day? ↗
The company's innovative engine continues to function well. 
Via The Motley Fool
Topics World Trade
News headline image
2 S&P 500 Dividend Stocks That Could Climb More Than 20% According to Wall Street Analysts ↗
Consensus price targets set by experts who follow these businesses are way above their recent prices. 
Via The Motley Fool
Topics Stocks
Chinese Drugmakers Flooded US With Wegovy Copy Ingredients — Now They Are Pivoting To Generics: Report ↗
Via Stocktwits
News headline image
Down 34%, Should You Buy the Dip on Viking Therapeutics? ↗
Viking aims to enter the billion-dollar weight loss drug market. 
Via The Motley Fool
News headline image
FDA Breakthrough Status Awarded To Lilly-Merck Combo Drug For Advanced Non-Small Cell Lung Cancer ↗
Eli Lilly's olomorasib with Merck's Keytruda receives FDA Breakthrough Therapy status for KRAS G12c lung cancer, supported by trial results. 
Via Benzinga
News headline image
ETF Traders Are Quietly Positioning For Market Turbulence: Direxion ↗
Direxion MD Edward Egilinsky says traders are locking profits, hedging market highs, and using Palantir inverse ETFs for tactical moves. 
Via Benzinga
Topics ETFs
News headline image
Prediction: These 2 Biotech Stocks Could Double in the Next 5 Years ↗
Both companies have made significant progress in recent years. 
Via The Motley Fool
News headline image
The 6 Best Stocks to Buy Right Now in September (2025)! ↗
There is something for everyone in this list of excellent stocks to buy. 
Via The Motley Fool
News headline image
Where Will Eli Lilly Be in 3 Years? ↗
The weight-loss drug opportunity could approach $100 billion by the end of the decade. 
Via The Motley Fool
Topics Intellectual Property
News headline image
The Problem With Weight Loss Stocks ↗
There are new ways to tackle weight loss, but the stocks leading the way are lagging. 
Via The Motley Fool
Topics Economy
News headline image
After Copycat Boom, China's Drugmakers Target Global Generics ↗
Chinese suppliers of semaglutide and tirzepatide that fueled a U.S. weight-loss drug boom are pivoting to generics as FDA crackdowns. 
Via Benzinga
Topics Supply Chain
News headline image
This House of Representative Just Bought Up To $245K In Eli Lilly Stock ↗
 
Via Benzinga
News headline image
Defiance Launches LLYZ: The First 2X Short ETF for Eli Lilly
From Defiance ETFs
Via GlobeNewswire
News headline image
Is Novo Nordisk Stock a Buy Now? ↗
A 57% risk reduction for heart attacks and strokes sounds like an amazing result. 
Via The Motley Fool
News headline image
Inflation's Stubborn Grip: PCE Index and Fed's Dilemma
The specter of persistent inflation continues to loom large over the U.S. economy, keeping both consumers and policymakers on edge. Despite the Federal Reserve's aggressive campaign of interest rate... 
Via MarketMinute
Topics Bonds Economy Supply Chain
News headline image
EXCLUSIVE: August's 20 Most-Searched Tickers On Benzinga Pro – Where Do Opendoor, Palantir, BitMine Immersion, Apple Stock Rank? ↗
Each trading day features hundreds of headlines and press releases on Benzinga Pro, a source for traders to see the latest news on the overall market and individual tickers. 
Via Benzinga
News headline image
Novo Nordisk's Wegovy Outshines Eli Lilly's Tirzepatide In Reducing Risk Of Heart Attack, Stroke And Death ↗
Novo Nordisk's Wegovy cut cardiovascular risks significantly versus tirzepatide in a real-world study, showing fewer heart attacks, strokes, and deaths. 
Via Benzinga
News headline image
Unpacking Q2 Earnings: Elanco (NYSE:ELAN) In The Context Of Other Pharmaceuticals Stocks
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Elanco (NYSE:ELAN) and the best and worst... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Benzinga Bulls And Bears: Eli Lilly, Firefly, Marvell — And Trump Investment Hints Boost Defense Stocks ↗
Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories. 
Via Benzinga
Topics Government
News headline image
FDA Approves Biogen, Eisai's Highly Anticipated Alzheimer's Treatment ↗
This could put pressure on Eli Lilly, which sells a competing drug called Kisunla. 
Via Investor's Business Daily
News headline image
The Great Rebalancing: Equity Markets Pivot from Tech Giants to Value and Cyclical Stocks
A significant sector rotation is currently underway in equity markets, shifting investor capital away from the mega-cap technology stocks that dominated recent years towards more traditional value and... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
Eli Lilly Is Proof That Wall Street Stars Don't Have To Be Tech Titans ↗
 
Via Benzinga
News headline image
Novo Nordisk Slowdown Weighs On Denmark's Economic Outlook ↗
Novo Nordisk alone contributing one-fifth of employment gains to Denmark. But economic headwinds are mounting. 
Via Benzinga
News headline image
FDA Tightens Safety Guidelines For Biogen Leqembi Alzheimer's Therapy ↗
The FDA now requires earlier MRI screening for Alzheimer's drug Leqembi to detect ARIA-E, a rare but serious side effect, aiming to improve treatment safety for patients. 
Via Benzinga
News headline image
Nvidia's $46.7 Billion Quarter Shows the AI Trade Is Alive and Well -- With Caveats ↗
Here's why investors aren't sure what to make of Nvidia earnings. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
2 Beaten-Down Stocks That Could Rocket 142% to 222% Higher, According to Wall Street Analysts ↗
Investment bank analysts up and down Wall Street are pounding the table on these stocks. 
Via The Motley Fool
News headline image
The Unsettling Dance: Robust Growth and Stubborn Inflation Challenge the Fed's Resolve
The U.S. economy currently navigates an intriguing, yet precarious, path as hypothetical Q2 2025 data suggests a robust rebound in Gross Domestic Product (GDP) growth. This economic buoyancy, however,... 
Via MarketMinute
Topics Bonds Economy Energy
News headline image
Global Trade Braces for Impact: US-China Tariff Tensions Persist Amidst Fleeting Truces and Escalating Duties
The global economic landscape remains deeply entrenched in a complex and often volatile trade conflict between the United States and China. What began in January 2018 as a series of targeted duties has... 
Via MarketMinute
Topics Artificial Intelligence Economy Government
< Previous 1 2
...
26 27 28 29 30 31 32 33 34
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.